Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 6, 2004, Pages 2233-2243

  Salvati, Anna L ^a   De Dominicis, Alessandra ^a   Tait, Sabrina ^a   Canitano, Andrea ^a   Lahm, Armin ^b   Fiore, Lucia ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3(2H) ISOFLAVONE; ANTIVIRUS AGENT; ISOFLAVONE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN 1; VIRUS RECEPTOR;

AMINO ACID SUBSTITUTION; ARTICLE; CONFORMATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HYDROPHOBICITY; MOLECULAR BIOLOGY; NONHUMAN; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 2; PRIORITY JOURNAL; VIROLOGY; VIRUS CAPSID; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN;

ALGORITHMS; ANTIVIRAL AGENTS; CAPSID; CAPSID PROTEINS; CENTRIFUGATION, DENSITY GRADIENT; DRUG RESISTANCE, VIRAL; HEAT; HELA CELLS; HUMANS; ISOFLAVONES; MODELS, MOLECULAR; MUTATION; PHENOTYPE; POLIOVIRUS; RECOMBINANT PROTEINS; RNA, VIRAL; TRANSFECTION; VIRUS REPLICATION;

EID: 2542501627     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.6.2233-2243.2004     Document Type: Article

References (56)

1. Bauer, D. J., J. W. T. Selway, J. F. Batchelor, M. Tísdale, I. C. Caldwell, and D. A. B. Young. 1981. 4′,6-Dichloroflavan (BW683C), a new anti-rhinovirus compound. Nature 292:369-370.
2. Bayer, N., E. Prchla, M. Schwab, D. Blaas, and R. Fuchs. 1999. Human rhinovirus HRV14 uncoats from early endosomes in the presence of bafilomycin. FEBS Lett. 463:175-178.
3. Berman, H. M., J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissing, I. N. Shindyalov, and P. E. Bourne. 2000. The Protein Data Bank. Nucleic Acids Res. 28:235-242.
4. Burali, C., N. Desideri, M. L. Stein, C. Conti, and N. Orsi. 1987. Synthesis and anti-rhinovirus activity of halogen-substituted isoflavenes and isoflavanes. Eur. J. Med. Chem. 22:119-123.
5. Caliguiri, L. A., J. J. McSharry, and G. W. Lawrence. 1980. Effect of arildone on modifications of poliovirus in vitro. Virology 105:86-93.
6. Centers for Disease Control and Prevention. 2002. Progress toward global eradication of poliomyelitis, 2001. Morb. Mortal. Wkly. Rep. 51:253-256.
7. Centers for Disease Control and Prevention. 2002. Acute flaccid paralysis associated with circulating vaccine-derived poliovirus: Philippines 2001. JAMA 287:311.
8. Centers for Disease Control and Prevention. 2002. Public health dispatch: poliomyelitis, Madagascar, 2002. Morb. Mortal. Wkly. Rep. 51:622.
9. Conti, C., D. Genovese, R. Santoro, M. L. Stein, N. Orsi, and L. Fiore. 1990. Activities and mechanisms of action of halogen-substituted flavonoids against poliovirus type 2 infection in vitro. Antimicrob. Agents Chemother. 34:460-466.
10. Danthi, P., M. Tosteson, Q.-H. Li, and M. Chow. 2003. Genome delivery and ion channel properties are altered in VP4 mutants of poliovirus. J. Virol. 77:5266-5274.
11. Filman, D. J., R. Syed, M. Chow, A. J. Macadam, P. D. Minor, and J. M. Hogle. 1989. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J. 8:1567-1579.
12. Fiore, L., B. Ridolfi, D. Genovese, G. Buttinelli, S. Lucioli, A. Lahm, and F. M. Ruggeri. 1997. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies. J. Virol. 71:6905-6912.
13. Fox, M. P., M. J. Otto, and M. A. McKinlay. 1986. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob. Agents Chemother. 30:110-116.
14. Fricks, C. E., and J. M. Hogle. 1990. Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J. Virol. 64:1934-1945.
15. Genovese, D., S. Catone, M. E. Farah, A. Gambacorta, and L. Fiore. 1999. Isolation and biological characterization of 3(2H)-isoflavene-resistant and -dependent poliovirus type 2 Sabin variants. J. Gen. Virol. 80:157-167.
16. Genovese, D., C. Conti, P. Tomao, N. Desideri, M. L. Stein, S. Catone, and L. Fiore. 1995. Effect of chloro-, cyano-, and amidino-substituted flavonoids on enterovirus infection in vitro. Antivir. Res. 27:123-136.
17. Grant, R. A., C. N. Hiremath, D. J. Filman, R. Syed, K. Andries, and J. M. Hogle. 1994. Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr. Biol. 4:784-797.
18. Halliday, E., J. Winkelstein, and A. D. Webster. 2003. Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality. J. Infect. 46:1-8.
19. Hayden, F. G., D. T. Herrington, T. L. Coats, K. Kim, E. C. Cooper, S. A. Villano, S. Liu, S. Hudson, D. C. Pevear, M. Collett, M. McKinlay, and Pleconaril Respiratory Infection Study Group. 2003. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin. Infect. Dis. 36:1523-1532.
20. Heinz, B. A., R. R. Rueckert, D. A. Shepard, F. J. Dutko, M. A. McKinlay, M. Fancher, M. G., Rossmann, J. Badger, and T. J. Smith. 1989. Genetic and molecular analyses of spontaneous variants of human rhinovirus 14 that are resistant to an antiviral compound. J. Virol. 63:2476-2485.
21. Hogle, J. M. 2002. Poliovirus cell entry: common structural themes in viral cell entry pathways. Annu. Rev. Microbiol. 56:677-702.
22. Hogle, J. M., M. Chow, and D. J. Filman. 1985. Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229:1358-1365.
23. Hull, H. F. 2001. Progress towards global polio eradication. Dev. Biol. 105:3-7.
24. Kew, O. M., V. Morris-Glasgow, M. Landaverde, C. Burns, J. Shaw, Z. Garib, J. Andre, E. Blackman, C. J. Freeman, J. Jorba, R. Sutter, G. Tambini, L. Venczel, C. Pedreira, F. Laender, et al. 2002. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296:356-359.
25. Kim, K. H., P. Willingmann, Z. X. Gong, M. J. Kremer, M. S. Chapman, I. Minor, M. A. Oliveira, M. G. Rossmann, K. Andries, G. D. Diana, et al. 1993. A comparison of the anti-rhinoviral drug binding pocket in HRV14 and HRV1A. J. Mol. Biol. 230:206-227.
26. Lentz, K. N., A. D. Smith, S. C. Geisler, S. Cox, P., Buontempo, A. Skelton, J. DeMartino, E. Rozhon, J. Schwartz, V. Girijavallabhan, J. O'Connell, and E. Arnold. 1997. Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973, comparison of the structural and biological properties of three poliovirus serotypes. Structure 15:961-978.
27. Macadam, A. J., C. Arnold, J. Howlett, A. John, S. Marsden, et al. 1989. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccines. Virology 172:408-414.
28. Martin, J., G. Dunn, R. Hull, V. Patel, and P. D. Minor. 2000. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J. Virol. 74:3001-3010.
29. Martin, J., E. Samoilovich, G. Dunn, A. Lackenby, E. Feldman, A. Heath, E. Svirchevskaya, G. Cooper, M. Yermalovich, and P. D. Minor. 2002. Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis. J. Virol. 76:10921-10928.
30. McKinlay, M. A. 2001. Recent advances in the treatment of rhinovirus infections. Curr. Opin. Pharmacol. 1:477-481.
31. Melnick, J. L. 1996. Current status of poliovirus infections. Clin. Microbiol. Rev. 9:293-300.
32. Mendelsohn, C. L., E. Wimmer, and V. R. Racaniello. 1989. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56:855-865.
33. Mosser, A. G., and R. Rueckert. 1993. WIN-51711-dependent variants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present. J. Virol. 67:1246-1254.
34. Mosser, A. G., J. Y. Sgro, and R. R. Rueckert. 1994. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J. Virol. 68:8193-8201.
35. Mosser, A. G., D. A. Shepard, and R. R. Rueckert. 1994. Use of drug-resistance variants to identify functional regions in picornavirus capsid proteins. Arch. Virol. 9:111-119.
36. Oliveira, M. A., R. Zhao, W. M. Lee, M. J. Kremer, I. Minor, R. R. Rueckert, G. D. Diana, D. C. Pevear, F. J. Dutko, M. A. McKinlay, et al. 1993. The structure of human rhinovirus 16. Structure 1:51-68.
37. Pallansch, M. A., and R. P. Roos. 2001. Enteroviruses: polioviruses, coxsackieviruses, echoviruses and newer enteroviruses, p. 723-775. In B. N. Fields, D. Knipe, and P. Howley (ed.), Virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
38. Perchla, E., E. Kuechler, D. Blaas, and R. Fuchs. 1994. Uncoating of human rhinovirus serotype 2 from late endosomes. J. Virol. 68:3713-3723.
39. Pevear, D. C., M. J. Fancher, P. J. Felock, M. G. Rossmann, M. S. Miller, G. Diana, A. M. Treasurywala, M. A. McKinlay, and F. J. Dutko. 1989. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J. Virol. 63:2002-2007.
40. Pevear, D. C., T. M. Tull, M. E. Seipel, and J. M. Groake. 1999. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother 43:2109-2115.
41. Pollard, S. R., G. Dunn, N. Cammack, P. D. Minor, and J. Almond. 1989. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J. Virol. 63:4949-4951.
42. Racaniello, V. R. 2001. Picornaviridae: the viruses and their replication, p. 685-722. In B. N. Fields, D. Knipe, and P. Howley (ed.), Virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
43. Rogers, J. M., J. D. Diana, and M. A. McKinlay. 1999. Pleconaril. A broad spectrum antipicornaviral agent. Adv. Exp. Med. Biol. 458:69-76.
44. Rombaut, B., K. Andries, and A. Boeye. 1991. A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids. J. Gen. Virol. 72:2153-2157.
45. Rossmann, M. G., E. Arnold, J. W. Erickson, E. A. Frankenberger, J. P. Griffith, H. J. Hecht, J. E. Johnson, G. Kamer, M. Luo, A. G. Mosser, et al. 1985. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317:145-153.
46. Rotbart, H. A. 1999. Antiviral therapy for enteroviral infections. Pediatr. Infect. Dis. J. 18:632-633.
47. Rotbart, H. A., A. D. Webster, and the Pleconaril Treatment Registry Group. 2001. Treatment of potentially life-threatining enterovirus infections with pleconaril. Clin. Infect. Dis. 32:228-235.
48. Rueckert, R. R. 1996. Picornaviridae: the viruses and their replication, p. 723-775. In B. N. Fields, D. Knipe, and P. Howley (ed.), Virology, 3rd ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
49. Smith, T. J., M. J. Kremer, M. Luo, G. Vriend, E. Arnold, G. Kamer, M. G. Rossmann, M. A. McKinlay, G. D. Diana, and M. J. Otto. 1986. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 233:1286-1293.
50. Smyth, M., T. Pettitt, A. Symonds, and J. Martin. 2003. Identification of the pocket factors in a picornavirus. Arch. Virol. 148:1225-1233.
51. Superti, F., L. Seganti, N. Orsi, M. Divizia, R. Gabrieli, A. Pana, and M. L. Stein. 1989. Effect of isoflavans and isoflavenes on the infection of Frp/3 cells by hepatitis A virus. Antivir. Res. 11:247-254.
52. Tisdale, M., and W. T. Selway. 1984. Effect of dichloroflavan (BW683C) on the stability and uncoating of rhinovirus type 1B. J. Antimicrob. Chemother. 14(Suppl. A):97-105.
53. Toyoda, H., M. Kohara, Y. Kataoka, T. Suganuma, T. Omata, N. Imura, and A. Nomoto. 1984. Complete nucleotide sequence of all three serotype genomes. Implications for genetic relationship, gene function and antigenic determinants. J. Mol. Biol. 174:561-585.
54. Vance, L., N. Moscufo, M. Chow, and B. A. Heinz. 1997. Poliovirus 2C region functions during encapsidation of viral RNA. J. Virol. 71:8759-8765.
55. Webster, D. 2000. The potential use of anti-enteroviral drugs in the immunocompromised. Curr. Opin. Infect. Dis. 13:625-629.
56. Zeichardt, H., M. J. Otto, M. A. McKinley, P. Willingmann, and K. O. Habermehl. 1987. Inhibition of poliovirus uncoating by disoxaril (WIN51711). Virology 160:281-285.